Preclinical studies have demonstrated that HDAC inhibitors can beneficially upregulate MHC molecule expression on tumor cells, enhancing antigen presentation, but these agents can also induce an adaptive upregulation of PD‐L1 expression, a potential mechanism of adaptive resistance. Here, HLA-C is linked to neoplasm.